Paul Tudor Jones’s PTC Therapeutics PTCT Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q2 | $1.12M | Sell |
13,739
-28,433
| -67% | -$2.05M | ﹤0.01% | 2341 |
|
|
2026
Q1 | $2.87M | Buy |
42,172
+34,760
| +469% | +$2.46M | 0.01% | 1581 |
|
|
2025
Q4 | $563K | Buy |
+7,412
| New | +$539K | ﹤0.01% | 2660 |
|
|
2025
Q2 | – | Sell |
-40,112
| Closed | -$2.04M | – | 3661 |
|
|
2025
Q1 | $2.04M | Sell |
40,112
-7,039
| -15% | -$351K | 0.01% | 1335 |
|
|
2024
Q4 | $2.13M | Buy |
47,151
+8,505
| +22% | +$364K | 0.01% | 1218 |
|
|
2024
Q3 | $1.43M | Sell |
38,646
-14,515
| -27% | -$486K | 0.01% | 1409 |
|
|
2024
Q2 | $1.63M | Buy |
53,161
+24,687
| +87% | +$800K | 0.01% | 1191 |
|
|
2024
Q1 | $828K | Sell |
28,474
-21,081
| -43% | -$590K | 0.01% | 1423 |
|
|
2023
Q4 | $1.37M | Buy |
+49,555
| New | +$1.13M | 0.01% | 1297 |
|
|
2022
Q4 | – | Sell |
-8,626
| Closed | -$433K | – | 2762 |
|
|
2022
Q3 | $433K | Sell |
8,626
-8,257
| -49% | -$405K | 0.01% | 1501 |
|
|
2022
Q2 | $676K | Buy |
16,883
+3,041
| +22% | +$107K | 0.02% | 1102 |
|
|
2022
Q1 | $516K | Buy |
13,842
+3,669
| +36% | +$141K | 0.01% | 1266 |
|
|
2021
Q4 | $405K | Sell |
10,173
-104,734
| -91% | -$4.01M | 0.01% | 1624 |
|
|
2021
Q3 | $4.28M | Buy |
114,907
+24,666
| +27% | +$1.01M | 0.07% | 321 |
|
|
2021
Q2 | $3.81M | Buy |
90,241
+53,087
| +143% | +$2.27M | 0.07% | 323 |
|
|
2021
Q1 | $1.76M | Buy |
37,154
+17,697
| +91% | +$1.05M | 0.04% | 578 |
|
|
2020
Q4 | $1.19M | Buy |
+19,457
| New | +$1.15M | 0.03% | 631 |
|
|
2019
Q4 | – | Sell |
-8,037
| Closed | -$272K | – | 1340 |
|
|
2019
Q3 | $272K | Buy |
+8,037
| New | +$350K | 0.01% | 883 |
|
|
2019
Q2 | – | Sell |
-10,612
| Closed | -$399K | – | 1291 |
|
|
2019
Q1 | $399K | Sell |
10,612
-8,738
| -45% | -$293K | 0.02% | 782 |
|
|
2018
Q4 | $664K | Buy |
19,350
+8,352
| +76% | +$300K | 0.01% | 508 |
|
|
2018
Q3 | $517K | Buy |
+10,998
| New | +$455K | 0.01% | 675 |
|
|
2018
Q1 | – | Sell |
-27,031
| Closed | -$451K | – | 1192 |
|
|
2017
Q4 | $451K | Buy |
27,031
+7,761
| +40% | +$131K | 0.01% | 651 |
|
|
2017
Q3 | $386K | Buy |
+19,270
| New | +$377K | 0.01% | 733 |
|
|
2017
Q2 | – | Sell |
-41,670
| Closed | -$410K | – | 1308 |
|
|
2017
Q1 | $410K | Buy |
+41,670
| New | +$504K | 0.01% | 804 |
|
|
2016
Q3 | – | Sell |
-10,500
| Closed | -$74K | – | 1669 |
|
|
2016
Q2 | $74K | Sell |
10,500
-72,927
| -87% | -$535K | ﹤0.01% | 1534 |
|
|
2016
Q1 | $537K | Buy |
+83,427
| New | +$1.45M | 0.01% | 894 |
|
|
2015
Q4 | – | Sell |
-9,400
| Closed | -$251K | – | 1794 |
|
|
2015
Q3 | $251K | Sell |
9,400
-400
| -4% | -$17.1K | 0.01% | 1215 |
|
|
2015
Q2 | $472K | Buy |
9,800
+6,486
| +196% | +$378K | 0.01% | 812 |
|
|
2015
Q1 | $202K | Sell |
3,314
-5,563
| -63% | -$339K | 0.01% | 1301 |
|
|
2014
Q4 | $460K | Buy |
8,877
+4,166
| +88% | +$183K | 0.02% | 783 |
|
|
2014
Q3 | $207K | Buy |
+4,711
| New | +$147K | 0.01% | 1183 |
|
Other funds holding PTCT
RI
JT
Paul Tudor Jones's PTCT Position: Q2 2026 in Review
Paul Tudor Jones reduced its PTC Therapeutics (PTCT) stake by 67% in Q2 2026, selling an estimated $2.05M and leaving 13,739 shares worth $1.12M. The position accounts for ﹤0.01% of the portfolio, ranked #2341.
Paul Tudor Jones first reported a position in PTCT in Q3 2014 and has held it in 31 quarters since. The position peaked at $4.28M in Q3 2021. 380 funds tracked by Wall St. Rank hold PTCT as of Q2 2026.
- Paul Tudor Jones held 13,739 shares of PTC Therapeutics worth $1.12M as of Q2 2026.
- Paul Tudor Jones sold 28,433 PTC Therapeutics shares in Q2 2026, an estimated $2.05M.
- PTC Therapeutics made up ﹤0.01% of Paul Tudor Jones's portfolio in Q2 2026, its #2341 holding.
- Paul Tudor Jones first reported a position in PTC Therapeutics in Q3 2014 and has held it in 31 quarters since.
- Paul Tudor Jones's PTC Therapeutics position peaked at $4.28M in Q3 2021.
- 380 funds tracked by Wall St. Rank held PTC Therapeutics as of Q2 2026.
Based on Tudor Investment Corp's 13F filing for Q2 2026, filed 14 Aug 2026.